Illumina VP & Distinguished Scientist Dr. Gary Schroth presents a short overview of genomic surveillance implications on vaccine efficacy. Sequencing-based surveillance helps public health officials track the path of the epidemic, understand transmission routes, determine the rate of viral evolution, and understand if the virus is changing in ways that impact therapeutic effectiveness. As a leader in next-generation sequencing, Illumina is working with researchers around the world to provide the vital capacity needed for a data-driven response.